Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

ALX Oncology

Onco_background

Oncology Today—December 8, 2025

This week’s oncology roundup covers major advances in targeted therapy,…

Oncology News

Oncology Video Recap—December 8, 2025

Explore our biweekly Oncology video recap highlighting major regulatory wins,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Hematology Today—December 8, 2025
Oncology Today—December 8, 2025
Oncology Video Recap—December 8, 2025
Lucid Diligence Brief: SciNeuro Pharmaceuticals $53M financing
Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer Ventures

Tags

AAV exit AI-designed phages Alligator Bioscience ANGPTL3 apixaban Autolus Biomea Fusion chronic rhinosinusitis cyclophosphamide Datopotamab Deruxtecan Denosumab Diagonal Therapeutics discovery platforms EASO guideline Eisai F2–F3 Factor Bioscience Fertility & Sterility Ganaplacide genome editing Heidelberg Pharma Infinity InnoCare Pharma innovative designs Ipsen Kyinsu modifiable risk factors neuropeptide Y Oncology investments pediatric ulcerative colitis Plozasiran precision diagnostics precision prostate cancer rimegepant RPDD RSRT Skin cancer Sonrotoclax Staphylococcus aureus vaccine SYMP syphilis Tavapadon THRβ agonist venture funding Venus P

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Hematology Today—December 8, 2025
Oncology Today—December 8, 2025
Oncology Video Recap—December 8, 2025
Lucid Diligence Brief: SciNeuro Pharmaceuticals $53M financing
Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer Ventures

TAGS

AAV exit AI-designed phages Alligator Bioscience ANGPTL3 apixaban Autolus Biomea Fusion chronic rhinosinusitis cyclophosphamide Datopotamab Deruxtecan Denosumab Diagonal Therapeutics discovery platforms EASO guideline Eisai F2–F3 Factor Bioscience Fertility & Sterility Ganaplacide genome editing Heidelberg Pharma Infinity InnoCare Pharma innovative designs Ipsen Kyinsu modifiable risk factors neuropeptide Y Oncology investments pediatric ulcerative colitis Plozasiran precision diagnostics precision prostate cancer rimegepant RPDD RSRT Skin cancer Sonrotoclax Staphylococcus aureus vaccine SYMP syphilis Tavapadon THRβ agonist venture funding Venus P

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy